A Federal Grant Built This Recovery Network. A Federal Letter Might Kill It.

Toni Fernandez was in seventh grade the first time she used opioids, in Colorado’s San Luis Valley, and she didn’t buy the pills or steal them. A classmate brought them to school. His father had been prescribed “large amounts of narcotics,” she remembers, “and he would just bring them and share them with us.” That’s how it started for a lot of kids in the Valley — not in an alley, but in a hallway, with pills that had a pharmacy’s name on the bottle. Two decades later, Fernandez is part of the reason the Valley now has a recovery network at all: peer support, treatment referrals, a community that didn’t exist when she needed it most, built in large part with federal dollars flowing through Medicaid and federal grants, according to reporting from the Colorado Sun.

That network is now under direct threat — not from a drug, but from paperwork.

The same government that spent two decades funding the infrastructure to keep people alive between relapses spent this year taking pieces of it back, one letter at a time.

This is not one policy. It’s three, landing in the same twelve months, on the same population, from two different federal agencies that don’t appear to be talking to each other. If you are a person in recovery, a case manager, or a facility administrator in Arizona — where every one of these three threads converges — you need to understand all three, because they compound.

The letter that reversed the letter

On April 24, 2026, the Substance Abuse and Mental Health Services Administration sent grantees around the country a pair of “Dear Colleague” letters. Together they banned federal grant dollars from being used to buy fentanyl, xylazine, or medetomidine test strips; sterile syringes; pipes; or to staff overdose hotlines, STAT News reported. Law enforcement drug-testing equipment was exempted. Overdose hotlines were not — SAMHSA’s own language described them as having “a primary function of facilitating illicit drug use by providing people using drugs a virtual or telephonic companion while they are using drugs,” according to Filter’s reporting on the letters.

Here’s the part that should stop you: this reverses a letter SAMHSA itself sent less than a year earlier, in July 2025, explicitly exempting test strips as “life-saving.” Tom Coderre, who led SAMHSA on an interim basis in 2021, once said publicly that giving people the tools to identify fentanyl in their own supply “will save lives.” That was the position of the same agency, under different leadership, five years apart. Nothing about fentanyl test strips changed in that time. What changed was who was answering the mail.

If you have ever dipped a strip before you used, you already know what a $1 piece of paper buys you: the difference between guessing and knowing. SAMHSA’s own numbers on what this costs the field are blunt — the agency’s staff has been cut from roughly 900 people to fewer than 450, alongside $1.7 billion in cancelled block grant funding and $350 million in addiction and overdose-prevention money pulled over fifteen months. The test-strip ban isn’t a standalone policy. It’s a symptom of an agency being hollowed out from the inside while it is still, on paper, the federal government’s primary addiction agency.

We have watched a government decide that a cheap thing which keeps people alive sends the wrong message before. In 1988, Congress — led by Senator Jesse Helms — banned federal funds from paying for syringe exchange programs, on the theory that clean needles “undercut the credibility of society’s message that drug use is illegal and morally wrong,” according to a CSIS history of the policy. That ban held for 21 years. It was lifted in December 2009, reinstated within two years by a budget deal, and only partially unwound after that. We are old enough, as a field, to recognize the shape of this argument. It has never once been right, and it has never once stopped mattering how many people it kills while it’s in effect.

We are old enough, as a field, to recognize the shape of this argument.

What the modeling says happens next

That last part isn’t rhetorical — it’s now a measured number. A microsimulation study out of the University of Colorado Anschutz Medical Campus, published in JAMA Network Open and covered in detail by News-Medical.net, modeled what happens to overdose mortality when syringe service program funding is cut by 11% and by 80%, over five years, for people who inject drugs. A “microsimulation” is exactly what it sounds like: instead of guessing at the top line, the model runs the decision through a simulated population of individuals and tracks what happens to each of them, then adds it up. Even the modest cut raised all-cause mortality. The severe cut was the one with a body count attached: 39,600 additional deaths overall, 15,600 of them from overdose, over five years.

“Disruptions to SSP funding are likely to have serious and measurable consequences,” said Kirk Fetters, MD, an infectious disease clinical fellow at CU Anschutz who worked on the study. His colleague Josh Barocas, MD, was more direct about what the programs actually do: “SSPs play a critical role in preventing overdose deaths and supporting vulnerable populations’ health.” Those aren’t advocacy talking points. They’re the conclusion of a peer-reviewed model, published the same season SAMHSA told grantees the tools those programs use are no longer an allowed expense.

The American Society of Addiction Medicine’s response to the SAMHSA letters was, notably, careful rather than furious — president Stephen Taylor said the organization was “continuing to carefully review” the guidance and preparing “to engage with federal partners” to keep policy evidence-based. Read that as what it is: the field’s leading clinical body choosing diplomacy over alarm, in a moment when the modeling says alarm might be the more honest response.

The other letter: Medicaid’s new math

If the SAMHSA letters were about tools, the second federal action is about coverage itself. In June 2026, the Centers for Medicare & Medicaid Services finalized a rule requiring most Medicaid expansion adults — in 43 states plus D.C. — to document 80 hours a month of work, community service, or schooling, or $580 in monthly earnings, starting January 1, 2027, Behavioral Health Business reported. Substance use disorder is a recognized exemption category. But it’s not automatic anymore. The rule requires what CMS calls a “functional impairment” test — proof that the condition significantly limits a person’s ability to work, not just a diagnosis on a chart. And the exemption specifically excludes people with five or more years of stable recovery.

Sit with that last clause for a second, because it is the whole argument in miniature. The reward for five years of sobriety, under this rule, is losing the exemption that assumed you couldn’t work because of the thing you no longer have. Debbie Witchey, president and CEO of the Association for Behavioral Health and Wellness, said CMS “listened to the behavioral health community” in shaping the final language — a genuinely fair characterization of a rule that could have been worse. Jennifer Tolbert, a policy analyst at KFF, described the more likely real-world outcome: people “falling through the cracks and losing coverage” — not because they’re not eligible, but because proving a functional impairment on a rolling basis is its own unpaid, undocumented, second job.

For a person in recovery, insurance instability isn’t administrative friction. It’s a clinical event. Losing coverage means losing a prescriber, a pharmacy relationship, a copay you can afford — the exact infrastructure that makes staying in recovery a repeatable daily act instead of a single act of will. States have about six months from the rule’s July 31, 2026 effective date to build verification systems capable of telling the difference between someone who’s working, someone who’s exempt, and someone who’s about to lose coverage because a form didn’t get filed. History says that system will not be built cleanly, and the people who fall through the gap in the meantime will not be an edge case. They will be the point.

History says that system will not be built cleanly, and the people who fall through the gap in the meantime will not be an edge case.

If you’re a case manager reading this: the “functional impairment” documentation for your clients with five or more years of stable recovery is the file to open this week, not in December. Build it now, while their prescriber and treatment history are easy to pull together, not during the scramble after a state sends a request you have thirty days to answer.

Arizona is next in line

Every one of these threads runs directly through Arizona, and the data is more layered than a single headline captures. Two things are both true and not contradictory: opioid-specific overdoses in Maricopa, Pima, and Pinal counties fell more than 50% year-over-year, Arizona’s Department of Health Services told FOX 10 Phoenix — real, hard-won progress on the specific drug class that’s been the state’s deadliest for a decade. At the same time, Arizona’s overall overdose death rate — across every substance, including the meth and heat-driven deaths that don’t show up in an opioid-only count — hit an all-time high of 43.5 per 100,000 people this year, roughly double the national rate. “The main thing in Arizona that differentiates us from the rest of the country is heat,” Dr. Matt Evans, an addiction medicine specialist at Circle the City, told KOLD News 13. Sixty-five percent of forty confirmed heat deaths in Maricopa County this summer involved substances. Two true numbers, two different lenses on the same crisis — and both point to a state that cannot absorb a federal retreat on tools or coverage right now.

Arizona has real levers here, if the state chooses to pull them. It’s due up to $1.215 billion in opioid settlement funds over 18 years, split roughly 56% to counties and cities and 44% to the state, money that isn’t subject to the SAMHSA grant restrictions because it isn’t SAMHSA money. AHCCCS opened a rural-focused grant this July specifically to fund naloxone distribution through first responders, rural clinics, and tribal partners — a genuinely useful, currently live program that predates and doesn’t depend on the federal test-strip ban. Neither of those levers offsets a Medicaid work-requirement rule that applies nationally, including to AHCCCS enrollees. But they are proof that state and settlement money can move independently of what Washington decides to fund this quarter — if the people holding it choose to move it toward the exact interventions the federal government just stepped back from.

What’s still yours

None of this is a reason to give up on any piece of it, and none of it should be read as the safety net disappearing all at once. Naloxone remains federally legal and, in most of the country including Arizona, free through public health departments, syringe programs, and pharmacies regardless of how this fight resolves — that is still yours, tonight, no functional-impairment test required. The 988 line still answers. Buprenorphine and methadone prescribing haven’t changed. What’s shifting is the plumbing behind those things — who pays for the test strip, who verifies the exemption, who keeps the hotline staffed — and plumbing failures take time to become visible on the surface. That’s exactly why they’re dangerous: by the time you can see the leak, the damage is already done upstream.

Toni Fernandez’s story didn’t end in seventh grade, and the San Luis Valley’s recovery network didn’t build itself in a single grant cycle. It took twenty years, a lot of people who stayed, and federal money that showed up reliably enough that a community could plan around it. That reliability is the thing actually being tested this year — not whether any single program survives one bad letter, but whether the people who built these networks can keep building faster than Washington can write the next one.

It took twenty years, a lot of people who stayed, and federal money that showed up reliably enough that a community could plan around it.

Rize tracks policy and funding changes affecting harm reduction access as they happen — including how they land in Arizona specifically.